Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Marina Konopleva(Albert Einstein College of Medicine), Aung Naing(The University of Texas MD Anderson Cancer Center), Cobi J. Heijnen(Rice University), Carlos Kamiya-Matsuoka(The University of Texas MD Anderson Cancer Center), Daniel D. Karp(The University of Texas MD Anderson Cancer Center), Maro Ohanian(The University of Texas MD Anderson Cancer Center), Carolina Salguero(The University of Texas MD Anderson Cancer Center), Christopher P. Vellano(The University of Texas MD Anderson Cancer Center), Christopher A. Bristow(The University of Texas MD Anderson Cancer Center), Prithviraj Bose(The University of Texas MD Anderson Cancer Center), Jing Han(Jiangnan University), Stefano Tiziani(Dell Children's Medical Center of Central Texas), Meghan Collins(The University of Texas at Austin), David S. Hong(The University of Texas MD Anderson Cancer Center), Sarina A. Piha‐Paul(The University of Texas MD Anderson Cancer Center), Sisi Gao(The University of Texas MD Anderson Cancer Center), Koji Sasaki(The University of Texas MD Anderson Cancer Center), Jordi Rodón(The University of Texas MD Anderson Cancer Center), Naval Daver(The University of Texas MD Anderson Cancer Center), Vivek Subbiah(Sarah Cannon), Apostolia M. Tsimberidou(The University of Texas MD Anderson Cancer Center), Siqing Fu(The University of Texas MD Anderson Cancer Center), Anand Kumar Singh(The University of Texas MD Anderson Cancer Center), Joseph R. Marszalek(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Musa Yılmaz(The University of Texas MD Anderson Cancer Center), Meenakshi B. Bhattacharjee(The University of Texas Health Science Center at Houston), Natalia Baran(The University of Texas MD Anderson Cancer Center), Jennifer R. Molina(The University of Texas MD Anderson Cancer Center), Mikhila Mahendra(The University of Texas MD Anderson Cancer Center), Annemieke Kavelaars(The University of Texas MD Anderson Cancer Center), Timothy P. Heffernan(The University of Texas MD Anderson Cancer Center), Philip Jones(The University of Texas MD Anderson Cancer Center), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Sonal Gera(The University of Texas MD Anderson Cancer Center), Shubham Pant(The University of Texas MD Anderson Cancer Center), Naveen Pemmaraju(The University of Texas MD Anderson Cancer Center), Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Alessia Lodi(The University of Texas at Austin), Qi Zhang(The University of Texas MD Anderson Cancer Center), Yuan Li(The University of Texas Health Science Center at Houston), Zhenlin Ju(The University of Texas MD Anderson Cancer Center), Jixiang Zhang(The University of Texas MD Anderson Cancer Center), Jason Gay(The University of Texas MD Anderson Cancer Center), Quanyun A. Xu(The University of Texas MD Anderson Cancer Center), Maria Emilia Di Francesco(The University of Texas MD Anderson Cancer Center), Ecaterina E. Dumbrava(The University of Texas MD Anderson Cancer Center), Farhad Ravandi(The University of Texas MD Anderson Cancer Center)
Cited by 372
Related Papers
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k